Moreover, this investigation delved into the association between LOX family member expression and the effectiveness of various antineoplastic treatments, including chemotherapy, targeted therapies and immunotherapy via multiplex immunofluorescence staining with pre‐treatment tumour specimens from breast, rectal and gastric cancer patients undergoing neoadjuvant therapy, as well as breast cancer organoids. Here, LOX is linked to gastric cancer.